Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

NASDAQ: ONTX was reduced by Zacks.com  from a “acquire” score to a “hold” rating in a research note provided to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It concentrates on uncovering and also creating small molecule medication candidates to treat cancer. The Business‘s items under various stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several various other equities research analysts additionally lately discussed the company. Noble Financial reissued a “buy” ranking and provided a $11.00 cost goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and established a “acquire” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating typical rate of $2.90 and also a two-hundred day moving typical price of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) earnings per share for the quarter, covering experts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as a negative internet margin of 8,294.27%. The firm had revenue of $0.06 million throughout the quarter, compared to the consensus quote of $0.06 million. Throughout the exact same quarter in the prior year, the company uploaded ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the present year.

A number of hedge funds have recently dealt shares of ONTX. GSA Resources Allies LLP got a brand-new placement in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Capital Monitoring LP purchased a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a brand-new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP purchased a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and various other institutional investors own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition and also development of oncology therapeutics. It focuses on uncovering and creating small molecule medicine candidates to treat cancer cells. The company was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To learn more regarding research offerings from Zacks Investment Research, check out Zacks.com.

This instantaneous news alert was produced by narrative scientific research innovation and financial data from Market in order to give viewers with the fastest and also most precise coverage. This story was evaluated by Market’s editorial group prior to publication. 



Before you consider Onconova Therapeutics, you’ll intend to hear this.

Market keeps track of Wall Street’s premier and finest doing research experts and also the stocks they recommend to their customers each day. Market has recognized the five stocks that cover experts are silently whispering to their clients to buy currently prior to the wider market catches on … and also Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics currently has a “Buy” rating amongst experts, top-rated analysts believe these five stocks are better gets.